Dr. Mahavir Agarwal is a psychiatrist by training who joined the University of Toronto Faculty in the spring of 2019. He is staff psychiatrist and Clinician-Scientist at the Centre for Addiction and Mental Health (CAMH) where he runs the Mental Health and Metabolism Clinic and the Clozapine Clinic in the Schizophrenia Division. His research interests lie in understanding the pathophysiology of metabolic and cognitive disturbances observed in schizophrenia, especially the severely elevated risk of obesity and type 2 diabetes observed in this population and the cognitive worsening that results from poor metabolic health. He is focusing on the role of insulin resistance in the brain in determining cognition and metabolic risk. To this end, he employs a multi-disciplinary approach to studying metabolic and cognitive outcomes using multi-modality neuroimaging, measures of cognitive functioning, and glucose metabolism (i.e. euglycemic pancreatic clamps and the oral glucose tolerance test).